August 12, 2024 03:43 PM EDT
Pharma
Law

J&J re­ceives sup­port for $6.5B talc set­tle­ment — re­port

Nicole DeFeudis

Editor

Ovar­i­an can­cer claimants have vot­ed in fa­vor of John­son & John­son’s pro­posed $6.5 bil­lion talc set­tle­ment plan, clear­ing the way for its sub­sidiary to file …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Roche's dual GLP-1/GIP re­sults show promis­ing weight loss, but al­so high rates of vom­it­ing

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

Ex­clu­sive: Bain scoops up $3B for fourth life sci­ences fund af­ter hand­ful of M&A deals

Roivant un­veils its next deal, hop­ing for TL1A-sized po­ten­tial from a shelved Bay­er lung dis­ease ther­a­py

Io­n­is’ $500M of­fer­ing; Terns aims to raise $125M 

A service from the Financial Times